Merck & Co., Inc. is listed as one of the 12 Most Undervalued Dow Stocks to Buy according to analysts. The company recently received FDA approval for a new subcutaneous injectable cancer therapy, KEYTRUDA QLEX, which is set to enhance patient convenience and efficiency.

In Europe, Merck & Co., Inc. received a positive opinion for ENFLONSIA, an RSV preventive for infants. Financially, the company reported strong Q2 2025 results, highlighting its vaccine franchise and innovative oncology treatments. MRK is also advancing novel drug candidates, such as raludotatug deruxtecan, with breakthrough FDA designation for ovarian cancer.

While MRK shows promise as an investment, certain AI stocks may offer greater upside potential and less downside risk. For those interested in an undervalued AI stock poised to benefit from Trump-era tariffs and onshoring trends, a free report is available. Check out the best short-term AI stock for more information.

Read more at Yahoo Finance: Merck & Co., Inc. (MRK) Advances Oncology Pipeline with Breakthrough FDA Designation for Ovarian Cancer Drug